BridgeBio Pharma, Inc. 4

BridgeBio Pharma CEO Neil Kumar sold an aggregate 13,900 shares of common stock (3,900 directly and 10,000 via a family trust) on August 18–19, 2026 at prices around $81–$86 per share under a Rule 10b5‑1 plan.

On August 18–19, 2026, BridgeBio Pharma, Inc. CEO Neil Kumar reported a series of open‑market sales of the company’s common stock, both from his direct holdings and from a family irrevocable trust. On August 18 he sold 3,900 shares directly in four tranches at weighted average prices ranging from about $81.15 to $83.77 per share, reducing his directly held position to 243,327 shares. On August 19, a family irrevocable trust for which he serves as co‑trustee sold an additional 10,000 shares in three tranches at prices around $83.86 to $85.65 per share, leaving that trust with 505,686 shares. The filing notes that these sales were executed under a Rule 10b5‑1 trading plan adopted on May 13, 2026, and that Kumar disclaims beneficial ownership of the trust‑held shares except to the extent of his pecuniary interest; he also reports substantial additional indirect holdings through the Kumar Haldea Revocable Trust (3,568,447 shares) and the NK 2026 GRAT (750,000 shares), indicating he continues to have a large economic exposure to BridgeBio after these transactions.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

4

Source Type

fda

Accession

0001470831-26-000848

Alert Tier

6